Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 3/20 | 0.35 |
| ▸ | SHMT1 | P34896 | 2/20 | 0.34 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 10/20 | 0.33 |
| ▸ | CNR1 | P21554 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23242481 | 0.81 | CTSB (0.37) | LPAR1SHMT1SHMT2CNR2CNR1 | |
| SCHEMBL22802601 | 0.79 | SHMT1 (0.33) | LPAR1SHMT1SHMT2CNR2CNR1 | |
| SCHEMBL29045057 | 0.78 | PTGDR2 (0.38) | LPAR1SHMT1SHMT2CNR2CNR1 | |
| SCHEMBL23242486 | 0.77 | CTSB (0.40) | SHMT1SHMT2CNR2CNR1ALDH1A1 | |
| SCHEMBL29966992 | 0.77 | CTSB (0.40) | SHMT1SHMT2CNR2CNR1ALDH1A1 | |
| SCHEMBL23265267 | 0.76 | CTSB (0.39) | SHMT1SHMT2CNR2CNR1ALDH1A1 | |
| SCHEMBL22802604 | 0.76 | ALDH1A1 (0.35) | LPAR1SHMT1SHMT2CNR2CNR1 | |
| SCHEMBL23265385 | 0.74 | SHMT1 (0.38) | SHMT1SHMT2CNR2CNR1ALDH1A1 | |
| SCHEMBL13502664 | 0.73 | CNR2 (0.42) | SHMT1SHMT2CNR2CNR1ALDH1A1 | |
| SCHEMBL23242482 | 0.72 | MAPT (0.40) | CNR2ALDH1A1CTSBCTSSEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11641857-B2 | Unusually potent ABA receptor pan-antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| US-20200397000-A1 | UNUSUALLY POTENT ABA RECEPTOR PAN-ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397000-A1 | UNUSUALLY POTENT ABA RECEPTOR PAN-ANTAGONISTS | AAK1, ATP5PO, BROX | LPAR1 871/4885SHMT1 2858/4885SHMT2 3159/4885 |
| US-11641857-B2 | Unusually potent ABA receptor pan-antagonists | AAK1, ATP5PO, BROX | LPAR1 871/4885SHMT1 2858/4885SHMT2 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.